A Case Where Switching the End Points for Clinical Trial Interpretation Might Be the Right Choice by Perrone, Francesco et al.
Copyright 2016 American Medical Association. All rights reserved.
A CaseWhere Switching the End Points for Clinical
Trial InterpretationMight Be the Right Choice
The first trial testing the efficacy of prolonging to a
total duration of 10 years an aromatase inhibitor (AI) as
adjuvant treatment of hormone receptor–positive
breast cancer has been reported at the 2016 American
Society of Clinical Oncology (ASCO) meeting and pub-
lished in the New England Journal of Medicine.1 In the
MA17R study, 1918 postmenopausal patients having
previously received 4.5 to 6 years of an AI, preceded in
most cases by tamoxifen, were randomized to 5 years
of letrozole or placebo. The primary end point was
disease-free survival (DFS) defined as the time from
randomization to breast cancer recurrence or a new
primary breast cancer, whichever came first. Death
(either owing or not owing to breast cancer) was not
included in the DFS definition, and patients who died
without breast cancer recurrence were censored at the
date of death. Coherently with study design and eligi-
bility criteria, median age was quite high, 65 years. The
high proportion of elderly patients and the low risk of
recurrence led to the fact that at the time of analysis
there were more deaths (100 in each arm) than breast
cancer recurrences or new primaries (67 and 98 with
letrozole and placebo, respectively). The primary
analysis showed a 4% advantage in 5-year DFS for the
letrozole arm (95% vs 91%) and an HR of 0.66 (95%
CI, 0.48-0.91), with a significant P value of .01. There
was no significant difference in overall survival. No
other time-to-event analyses were presented at ASCO,
and the message coming from the conference and the
press coverage was that postmenopausal patients
completing 5 years of aromatase inhibitors should or
might be offered further 5 years of treatment, not-
withstanding prudential comments of the discussants.
However, the article reports a posthoc analysis includ-
ing death within the DFS definition. Such analysis
actually shows that the absolute DFS advantage at 5
years is 2% (from 88% to 90%), the HR is 0.80 (95%
CI, 0.63-1.01) or 0.79 (95% CI, 0.63-1.00) if adjusted,
and the P value is no longer significant, .06 or .05 in
the unadjusted and adjusted analysis, respectively
(Table).
We argue that the primary end point chosen for
the MA17R study has limited clinical relevance, and
that the more reasonable interpretation of the trial
results should be based on the analysis that includes
death as event in the DFS definition. Therefore, the
study results should be interpreted as a nonsignificant,
very small advantage for patients receiving letrozole.
Of course, we recognize that it is methodologically and
conceptually wrong to interpret the results of a trial
through a secondary end point, ignoring the result of
the primary one. This matter is now addressed by the
COMPare team2 that is systematically checking the top
5 medical journals tracking which trials switched from
a primary to a secondary or unplanned outcome in the
interpretation of the results. On August 5, 2016, of
67 trials scrutinized only 9 were perfect, 354 out-
comes were omitted and 357 new outcomes were
added, that were unplanned in the protocol. We pre-
sume that in most cases of new added outcomes the
unplanned analyses supported a positive interpreta-
tion of the trial, whereby planned analyses were nega-
tive or not convincing enough. This would not be the
case for the MA17R trial, because the primary end
point is actually the one that overemphasizes the esti-
mated benefit.
Standardized definitions for efficacy end point in
trials of adjuvant treatment of breast cancer have been
proposed in 2010 in the so called STEEP system.3
Among the proposed definitions, there are none that
do not include deaths, at least those deaths owing to
breast cancer. Therefore, the DFS definition used in
the MA17R analysis is not included in the STEEP sys-
tem. A DFS analysis including breast cancer deaths,
and corresponding to the breast cancer-free interval
definition in the STEEP system, was planned a priori as
a sensitivity analysis. Obviously, it yielded the same
results of the primary analysis without deaths,
because breast cancer deaths by definition occur after
breast cancer recurrence, and therefore this analysis
was useless a priori, being informative only in the rare
case of a patient who died of breast cancer but with-
out knowledge of the recurrence date. The real issue,
however, is the exclusion of non–breast cancer deaths.
This type of event is expected to happen frequently in
an old population like the one eligible for this type of
trial, and clearly dilutes the clinical relevance of breast
cancer specific events. In this setting, death is a rel-
evant competing risk, because it is an alternative
outcome that is of equal or even more relevant clinical
importance than the primary outcome, and its occur-
rence alters the probability of the outcome of
interest.4 The use of a competing risk approach in the
statistical analysis has been defined as critical to accu-
rately determining disease risk for elderly individuals,
and therefore best inform clinical decision making.5
From this point of view, given that death was not
included in the definition of the primary end point, a
reasonable alternative tomodify the primary end point
could be performing a competing risk analysis
accounting for deaths.
We accept that it might make sense to exclude
death in early explanatory trials with new drugs, and
in a patient population not particularly at risk of
dying for other reasons. But we feel that this choice is
questionable in a pragmatic phase 3 trial, with an old
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drug, where the crucial issue is to decide on the relative value
of offering an up to 10-year extension of a treatment already
available in clinical practice, to a prevalently old population
of patients.
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Table. Summary of Disease-Free Survival Outcome
Characteristic
Not Including Death as an Event Including Death as an Event
Placebo
(n = 959)
Letrozole
(n = 959)
HR
(95% CI) P Value
Placebo
(n = 959)
Letrozole
(n = 959)
HR
(95% CI) P Value
No. of events 98 67 0.66
(0.48-0.91)
.01 (Adjusted) 100 100 0.80
(0.63-1.01)
.05 (Adjusted)
.06 (Unadjusted)
5-Year DFS, % 91 95 88 90
Abbreviations: DFS, disease-free survival, HR, hazard ratio.
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